1 Hybrid immunity improves B cell frequency, antibody potency and breadth against SARS-CoV-2 and 2 variants of concern

3 Emanuele Andreano¹, Ida Paciello¹, Giulia Piccini², Noemi Manganaro¹, Piero Pileri¹, Inesa
4 Hyseni^{2,3}, Margherita Leonardi^{2,3}, Elisa Pantano¹, Valentina Abbiento¹, Linda Benincasa³, Ginevra
5 Giglioli³, Concetta De Santi¹, Massimiliano Fabbiani⁴, Ilaria Rancan^{4,5}, Mario Tumbarello^{4,5},
6 Francesca Montagnani^{4,5}, Claudia Sala¹, Emanuele Montomoli^{2,3,6}, Rino Rappuoli^{1,7,*}

7

8 ¹Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy

9 ²VisMederi S.r.l, Siena, Italy

10 ³VisMederi Research S.r.l., Siena, Italy

11 ⁴Department of Medical Biotechnologies, University of Siena, Siena, Italy

12 ⁵Department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena University Hospital,
13 Siena, Italy

14 ⁶Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy

15 ⁷Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy

16

17 ***To whom correspondence should be addressed:** Dr. Rino Rappuoli rino.r.rappuoli@gsk.com

18

19 **Key words:** COVID-19; SARS-CoV-2; Monoclonal antibodies; Variants of concern; Vaccination; B
20 cell repertoire

21 **ABSTRACT**

22 To understand the nature of the antibody response to SARS-CoV-2 vaccination, we analyzed at
 23 single cell level the B cell responses of five naïve and five convalescent people immunized with the
 24 BNT162b2 mRNA vaccine. Convalescents had higher frequency of spike protein specific memory B
 25 cells and by cell sorting delivered 3,532 B cells, compared with 2,352 from naïve people. Of these,
 26 944 from naïve and 2,299 from convalescents produced monoclonal antibodies against the spike
 27 protein and 411 of them neutralized the original Wuhan SARS-CoV-2 virus. More than 75% of the
 28 monoclonal antibodies from naïve people lost their neutralization activity against the B.1.351 (beta)
 29 and B.1.1.248 (gamma) variants while this happened only for 61% of those from convalescents. The
 30 overall loss of neutralization was lower for the B.1.1.7 (alpha) and B.1.617.2 (delta) variants, however
 31 it was always significantly higher in those of naïve people. In part this was due to theIGHV2-5;IGHJ4-
 32 1 germline, which was found only in convalescents and generated potent and broadly neutralizing
 33 antibodies. Overall, vaccination of seropositive people increases the frequency of B cells encoding
 34 antibodies with high potency and that are not susceptible to escape by any of the four variants of
 35 concern. Our data suggest that people that are seropositive following infection or primary vaccination
 36 will produce antibodies with increased potency and breadth and will be able to better control SARS-
 37 CoV-2 emerging variants.

INTRODUCTION

Twenty months after the beginning of the COVID-19 pandemic, with 200 million people infected, 4.2 million deaths, and 3.9 billion vaccines doses administered, the world is still struggling to control the virus. In most developed countries vaccines have vastly reduced severe diseases, hospitalization and deaths, but they have not been able to control the infections which are fueled by new and more infectious variants. A large number of studies so far have shown that protection from infection is linked to the production of neutralizing antibodies against the spike protein (S protein) of the virus¹⁻⁴. This is a metastable, trimeric class 1 fusion glycoprotein, composed by the S1 and S2 subunits, and mediates virus entry changing from a prefusion to postfusion conformation after binding to the human angiotensin-converting enzyme 2 (ACE2) receptor and heparan sulfates on the host cells⁵. Potent neutralizing antibodies recognize the S1 subunit of each monomer which includes the receptor binding domain (RBD) and N-terminal domain (NTD) immunodominant sites⁶. The large majority of neutralizing antibodies bind the receptor binding motif (RBM), within the RBD, and a smaller fraction target the NTD^{3,7}. Neutralizing antibodies against the S2 subunit have been described, however they have very low potency^{3,8}. Neutralizing antibodies generated after infection derive in large part from germline IGHV3-53 and the closely related IGHV3-66 with very few somatic mutations^{9,10}. Starting from the summer of 2020, the virus started to generate mutations that allowed the virus to evade neutralizing antibodies, to become more infectious, or both. Some of the mutant viruses completely replaced the original Wuhan SARS-CoV-2. The most successful variant viruses are the B.1.1.7 (alpha), B.1.351 (beta), B.1.1.248 (gamma) and B.1.617.2 (delta) which have been named Variants of Concern (VoCs) by the World Health Organization¹¹. The delta variant is presently spreading across the globe and causing big concern also in fully vaccinated populations. It is therefore imperative to understand the molecular dynamics of the immune response to vaccination in order to design better vaccines and vaccination policies. Several investigators have shown that vaccination of convalescent people can yield neutralizing antibodies which can be up to a thousand-fold higher than those induced by infection or vaccination, suggesting that one way of controlling the pandemic may be the induction of a hybrid immunity-like response using a third booster dose¹²⁻¹⁶. Here we compared at single cell level the nature of the neutralizing antibody response against the original Wuhan virus and the VoCs in naïve and convalescent subjects immunized with the BNT162b2 mRNA vaccine. Naïve subjects were seronegative before vaccination while convalescent donors were already seropositive before vaccination. They will be named seronegatives and seropositives respectively in this work. Our data suggest that immunization of people already seropositive to the virus, increases the frequency, potency and breadth of neutralizing antibodies and may help to control emerging variants.

RESULTS

High levels of S protein specific memory B cells and plasma activity in seropositive vaccinees

In this study we enrolled 10 donors vaccinated with the BNT162b2 mRNA vaccine, 5 of them were healthy people naïve to SARS-CoV-2 infection at vaccination (seronegative) and other 5 had recovered from SARS-CoV-2 infection before vaccination (seropositive). Subject details are summarized in **Table S1**. We initially analyzed the B cell population frequencies between our groups. Seropositives showed a 2.46-fold increase in S protein specific CD19⁺CD27⁺IgD-IgM⁺ MBCs compared to seronegatives and an overall 10% higher level of CD19⁺CD27⁺IgD-IgM⁺ MBCs (**Figure S1A-B**). On the other hand, seronegatives showed a 2.3-fold higher frequency of CD19⁺CD27⁺IgD-IgM⁺ MBCs compared to seropositives. No differences were found in the levels of CD19⁺CD27⁺IgD-IgM⁺ S protein⁺ MBCs between the two groups assessed in this study (**Figure S1A-B**). Following the MBC analyses, we characterized the polyclonal response of these donors by testing their binding response to the S protein trimer, RBD, NTD and S2-domain, and subsequently by testing their neutralization activity against the original Wuhan SARS-CoV-2 virus (**Figure S2**). Plasma from seropositives showed a higher binding activity to the S protein and all tested domains compared to seronegatives (**Figure S2A - D**). In addition, seropositives showed a 10-fold higher neutralization activity against the original Wuhan SARS-CoV-2 virus compared to seronegatives (**Figure S2E - F**).

Frequency of neutralizing antibodies against the Wuhan virus and variants of concern

To better characterize the B cell immune response in seronegative and seropositive donors, we single cell sorted antigen-specific memory B cell (MBCs) using as bait the stabilized Wuhan SARS-CoV-2 S protein antigen which was encoded by the mRNA vaccine. The single cell sorting strategy was performed as previously described³. Briefly, MBCs prefusion S protein trimer-specific (S protein⁺), class-switched MBCs (CD19⁺CD27⁺IgD-IgM⁺) were single-cell sorted and then incubated for two weeks to naturally produce and release mAbs into the supernatant. A total of 2,352 and 3,532 S protein⁺ MBCs were sorted from seronegative and seropositive vaccinees respectively (**Table S2**). Of these 944 (40.1%) and 2,299 (65.1%) respectively, released in the supernatant monoclonal antibodies (mAbs) recognizing the S protein prefusion trimer in ELISA (**Figure 1A; Table S2**). These mAbs were then tested in a cytopathic effect-based microneutralization assay (CPE-MN) with the original Wuhan live SARS-CoV-2 virus at a single point dilution (1:5) to identify SARS-CoV-2 neutralizing human monoclonal antibodies (nAbs). This first screening identified a total of 411 nAbs, of which 71 derived from seronegatives and 340 were from seropositives(**Figure 1B; Table S2**). Overall, the fraction of S protein-specific B cells producing nAbs were 7.5% for seronegatives and 14.8% for seropositives. Following this first screening, all nAbs able to neutralize the Wuhan SARS-CoV-2 virus were tested by CPE-MN against major variants of concern (VoCs) including the B.1.1.7 (alpha), B.1.351 (beta) and B.1.1.248 (gamma) to understand the breadth of neutralization of nAbs elicited by the BNT162b2 mRNA vaccine. At the time of this assessment the B.1.617.2 (delta) variant was not yet spread globally and therefore it was not available for screening. Seropositives had an

overall higher percentage of nAbs neutralizing the VoCs compared to seronegatives. The average frequency of nAbs from seropositives neutralizing the alpha, beta and gamma variants was 80.6 (n=274), 39.4 (n=134) and 62.0% (n=211) respectively, compared to 70.4 (n=50), 22.5 (n=16) and 43.6% (n=31) respectively in seronegatives (**Figure 1C**; **Table S2**).

High potency and breadth of neutralization in seropositive COVID-19 vaccinees

To better characterize and understand the potency and breadth of coverage of all Wuhan SARS-CoV-2 nAbs, we aimed to express as immunoglobulin G1 (IgG1) all the 411 nAbs previously identified. We were able to recover and express 276 antibodies for further characterization, 224 (89.8%) from seropositives and 52 (10.2%) from seronegatives. Initially, antibodies were tested for binding against the RBD, NTD and the S2-domain of the original Wuhan SARS-CoV-2 S protein. Overall, no major differences were observed in nAbs that recognized the RBD and NTD with 71.2% (n=37) and 79.5% (n=178) nAbs binding the RBD, while 17.3% (n=9) and 16.5% (n=37) nAbs binding the NTD for seronegatives and seropositives respectively (**Figure S3**). None of the tested nAbs targeted the S2 domain. The biggest difference between groups was seen for nAbs able to bind the S protein only in its trimeric conformation i.e. not able to bind single domains. This class of nAbs was almost 3-fold higher in seronegatives compared to seropositives (**Figure S3**). nAbs were then tested by CPE-MN in serial dilution to evaluate their 100% inhibitory concentration (IC₁₀₀) against the Wuhan SARS-CoV-2 virus and the VoCs. At this stage of the study, the B.1.617.2 (delta) spread globally, and we were able to obtain the live virus for our experiments. Overall, nAbs isolated from seropositive vaccinees had a significantly higher potency than those isolated from seronegatives. The IC₁₀₀ geometric mean (GM-IC₁₀₀) in seropositives was 2.87, 2.17-, 1.17-, 1.43-, and 1.92-fold lower than in seronegatives for the Wuhan virus, the alpha, beta, gamma and delta VoCs respectively (**Figure 2**). In addition, a bigger fraction of nAbs from seropositives retained the ability to neutralize the VoCs. Indeed, when nAbs were individually tested against all VoCs, the ability to neutralize the alpha, beta, gamma and delta variants was lost by 14, 61, 61 and 29% of the antibodies from seropositives versus 32, 78, 75 and 46% respectively of those from seronegatives. The overall number of nAbs that lost neutralizing activity against the beta and gamma VoCs was very high, (75-78% in seronegatives and 61% in seropositives), while it was much lower for the alpha and delta variants (32-46% for seronegatives and 14-29% for seropositives) (**Figure 2**). Finally, a major difference between seronegatives and seropositives was found in the class of medium/high potency nAbs (IC₁₀₀ of 11-100 ng/mL and 101-1000 ng/mL) against all variants. Indeed, nAbs in these ranges from seropositives constitute the 71.0%, 62.5%, 23.7%, 22.8%, 53.1% of the whole nAbs repertoire while nAbs from seronegative donors were 48.1%, 38.5%, 17.3%, 17.3%, 34.6% against the Wuhan SARS-CoV-2 virus and alpha, beta, gamma and delta VoCs respectively (**Figure 2**).

Functional gene repertoire of neutralizing antibodies

The analysis of the immunoglobulin G heavy chain variable (IGHV) and joining (IGHJ) gene rearrangements of 58 and 278 sequences recovered from seronegative and seropositive subjects respectively, showed that they use a broad range of germ lines and share the most abundant. In particular, both groups predominantly used the IGHV1-69;IGHJ4-1 and IGHV3-53;IGHJ6-1, which were shared by three out of five subjects per each group (**Figure 3A**). In addition, the IGHV3-30;IGHJ6-1 and IGHV3-33;IGHJ4-1 germ lines, more abundant in seronegative donors, and IGHV1-2;IGHJ6-1, mainly expanded in seropositive vaccinees, were also used with high frequency in both groups. Only the IGHV2-5;IGHJ4-1 germline was seen to be predominantly expanded only in seropositive donors (**Figure 3A**). To better characterize these predominant gene families, we evaluated their neutralization potency and breadth against SARS-CoV-2 and VoCs. In this analyses we could not evaluate IGHV3-33;IGHJ4-1 nAbs, as only three of these antibodies were expressed, but we included the IGHV3-53 closely related family IGHV3-66;IGHJ4-1, as this family was previously described to be mainly involved in SARS-CoV-2 neutralization^{9,17}. A large part of nAbs deriving from these predominant germ lines had a very broad range of neutralization potency against the original Wuhan SARS-CoV-2 virus with IC₁₀₀ spanning from less than 10 to over 10,000 ng/mL (**Figure 3B - G**). However, many of them lost the ability to neutralize SARS-CoV-2 VoCs. The loss of neutralizing activity occurred for most germ lines and it was moderate against the alpha and delta variants, while it was dramatic against the beta and gamma variants (**Figure 3 B - G**). A notable exception was the IGHV2-5;IGHJ4-1 germline, present only in nAbs of seropositive patients, that showed potent antibodies able to equally neutralize all SARS-CoV-2 VoCs (**Figure 3D**). Finally, we evaluated the CDRH3-length and V-gene somatic hyper mutation (SHM) levels for all nAbs retrieved from seronegatives and seropositives and for predominant germ lines. Overall, the two groups show a similar average CDRH3-length (15.0 aa and 15.1 aa for seronegatives and seropositives respectively), however seropositives showed almost 2-fold higher V-gene mutation levels compared to seronegatives (**Figure S4**). As for predominant gene derived nAbs, we observed heterogeneous CDRH3-length, with the only exception of IGHV3-53;IGHJ6-1 nAbs, and higher V-gene mutation levels in seropositives predominant germ lines compared to seronegatives (**Figure S5**).

Epitope mapping of neutralizing antibodies

To map the regions of the S protein recognized by the identified nAbs we used a competition assay with four known antibodies: J08, which targets the top loop of the receptor binding motif (RBM)³, S309, which binds the RBD but outside of the RBM region¹⁸, 4A8, that recognized the NTD¹⁹, and L19, that binds the S2-domain³(**Figure S6**). The nAbs identified in this study were pre-incubated with the original Wuhan SARS-CoV-2 S protein and subsequently the four nAbs labeled with different fluorophores were added as single mix. 50% signal reduction for one of the four fluorescently labelled nAbs, was used as threshold for positive competition. The vast majority of nAbs from both seronegative (50.0%; n=26) and seropositive (51.3%; n=115) vaccinees competed with J08 (**Figure 4A; Table S3**). For seronegatives, the second most abundant population was composed by nAbs

185 that did not compete with any of the four fluorescently labelled nAbs (25.0%; n=13) followed by nAbs
186 targeting the NTD (17.3%; n=9). As for seropositives, the second most abundant population was
187 composed by nAbs that competed with S309 (21.4%; n=48) followed by nAbs competing with 4A8
188 (15.6%; n=35) and not-competing nAbs (11.6%; n=26). None of our nAbs did compete with the S2
189 targeting antibody L19 (**Figure 4A; Table S3**). nAbs competing with J08, which are likely to bind the
190 RBM, derived from several germ lines, including the predominant IGHV3-53;IGHJ6-1 (10.6%; n=14),
191 IGHV1-69;IGHJ4-1 (8.3%; n=11) and IGHV1-2;IGHJ6-1 (6.8%; n=9) (**Figure 4B**). In contrast, those
192 competing with S309 derived mostly from germline IGHV2-5;IGHJ4-1 (13.7%; n=7) which were
193 isolated exclusively from seropositive vaccinees (**Figure 4C**). As for NTD-directed nAbs the non-
194 predominant gene family IGHV1-24;IGHJ6-1 was the most abundant confirming what was reported
195 in previous studies (**Figure 4D**)²⁰. Finally, for nAbs that did not compete with any of the known
196 antibodies used in our competition assay, the non-predominant gene families IGHV1-69;IGHJ3-1
197 (9.7%; n=3) and IGHV1-69;IGHJ6-1 (9.7%; n=3) were the most abundant (**Figure 4E**).

198 DISCUSSION

199 Our study analyzed for the first time at single cell level the repertoire of B cells producing neutralizing
200 antibodies following vaccination of naïve and previously infected people. The most important
201 conclusion from this work is that vaccinating people that are already seropositive to the virus,
202 because of previous SARS-CoV-2 infection, induces neutralizing antibodies which are more potent
203 and less susceptible to escape from SARS-CoV-2 variants. This conclusion is not surprising since
204 several papers have already reported that vaccination of convalescent people induces a hybrid
205 immunity with titers of neutralizing antibodies up to 50-fold higher than those induced by vaccination
206 of naïve people^{15,16}. The novelty of our work lies in the molecular analysis of this response which
207 shows that seropositive subjects respond to vaccination with more B cells producing antibodies
208 which show higher neutralization potency and are not susceptible to escape variants. In part this is
209 due to potent antibodies derived from theIGHV2-5;IGHJ4-1 germline which was only found in
210 seropositive people. The absence of this germline in naïve vaccinees is also confirmed by previous
211 studies¹⁶. One limitation of our study is that we did not include people that received a third booster
212 dose of vaccine, as at the time that this work was being performed no policies for a third booster
213 dose were implemented. In spite of this limitation, we believe that our conclusions are likely to be
214 extendable to people that are seropositives following primary vaccination. Indeed, the S protein
215 produced following vaccination with mRNA, viral vectors or following infection is produced in all
216 cases by the cell of the host and it is likely to be presented to the immune system in a similar manner
217 and generate a similar antibody response. This is confirmed by the fact that neutralizing antibodies
218 following infection and vaccination derive mostly from the same immunodominant germ lines, i.e.
219 IGHV3-53, 3-30 and 3-66^{9,10,16,17}. Our analysis suggests that a booster dose of vaccine will increase
220 the frequency of memory B cells producing potent neutralizing antibodies not susceptible to escape
221 variants and allow better control of this pandemic. Our work also shows that more than three quarters
222 of antibodies neutralizing the Wuhan virus do not neutralize at all the beta and gamma variants, while
223 the fraction of antibodies not neutralizing the alpha and delta variants is much smaller and in all
224 cases below 50%. This suggest that the beta and gamma variants were originally selected to escape
225 natural immunity, while the alpha and gamma were selected mostly for their increased infectivity and
226 ability to spread in the population^{21,22}. The massive escape from predominant germ lines, such as
227 IGHV3-53, 3-66, 3-30 and 1-69, and the presence of antibodies deriving from germline IGHV2-5 that
228 are completely insensitive to the existing variants, suggest that the design of vaccines that
229 preferentially promote or avoid the expansion of selected germ lines can generate broad protection
230 against SARS-CoV-2 variants. Germline-targeting vaccination, which has been pioneered in the HIV
231 field^{23,24}, may be a promising strategy to fight the COVID-19 pandemic.

232 MATERIALS & METHODS

233 Enrollment of COVID-19 vaccinees and human sample collection

234 This work results from a collaboration with the Azienda Ospedaliera Universitaria Senese, Siena (IT)
235 that provided samples from COVID-19 vaccinated donors, of both sexes, who gave their written
236 consent. The study was approved by local ethics committees (Parere 17065 in Siena) and conducted
237 according to good clinical practice in accordance with the declaration of Helsinki (European Council
238 2001, US Code of Federal Regulations, ICH 1997). This study was unblinded and not randomized.
239 No statistical methods were used to predetermine sample size.

241 Single cell sorting of SARS-CoV-2 S protein⁺ memory B cells from COVID-19 vaccinees

242 Peripheral blood mononuclear cells (PBMCs) and single cell sorting strategy were performed as
243 previously described³. Briefly, PBMC were isolated from heparin-treated whole blood by density
244 gradient centrifugation (Ficoll-Paque™ PREMIUM, Sigma-Aldrich). After separation, PBMC were
245 stained with Live/Dead Fixable Aqua (Invitrogen; Thermo Scientific) diluted 1:500 at room
246 temperature RT. After 20 min incubation cells were washed with PBS and unspecific bindings were
247 saturated with 20% normal rabbit serum (Life technologies). Following 20 min incubation at 4°C cells
248 were washed with PBS and stained with SARS-CoV-2 S-protein labeled with Strep-Tactin®XT DY-
249 488 (iba-lifesciences cat# 2-1562-050) for 30 min at 4°C. After incubation the following staining mix
250 was used CD19 V421 (BD cat# 562440), IgM PerCP-Cy5.5 (BD cat# 561285), CD27 PE (BD cat#
251 340425), IgD-A700 (BD cat# 561302), CD3 PE-Cy7 (BioLegend cat# 300420), CD14 PE-Cy7
252 (BioLegend cat# 301814), CD56 PE-Cy7 (BioLegend cat# 318318) and cells were incubated at 4°C
253 for additional 30 min. Stained MBCs were single cell-sorted with a BD FACS Aria III (BD Biosciences)
254 into 384-well plates containing 3T3-CD40L feeder cells and were incubated with IL-2 and IL-21 for
255 14 days as previously described²⁵.

257 ELISA assay with SARS-CoV-2 S protein prefusion trimer

258 mAbs and plasma binding specificity against the S-protein trimer was detected by ELISA as
259 previously described³. Briefly, 384-well plates (microplate clear, Greiner Bio-one) were coated with
260 3 µg/mL of streptavidin (Thermo Fisher) diluted in carbonate-bicarbonate buffer (E107, Bethyl
261 laboratories) and incubated at RT overnight. The next day, plates were incubated 1 h at RT with
262 3µg/mL of SARS-CoV-2 S protein diluted in PBS. Plates were then saturated with 50 µL/well of
263 blocking buffer (phosphate-buffered saline, 1% BSA) for 1 h at 37°C. After blocking, 25 µL/well of
264 mAbs diluted 1:5 in sample buffer (phosphate-buffered saline, 1% BSA, 0.05% Tween-20) were
265 added to the plates and were incubated at 37°C. Plasma samples derived from vaccinees were
266 tested (starting dilution 1:10; step dilution 1:2 in sample buffer) in a final volume of 25 µL/well and
267 were incubated at 37°C. After 1 h of incubation, 25 µL/well of alkaline phosphatase-conjugated goat
268 antihuman IgG and IgA (Southern Biotech) diluted 1:2000 in sample buffer were added. Finally, S
269 protein binding was detected using 25 µL/well of PNPP (p-nitrophenyl phosphate;Thermo Fisher)

and the reaction was measured at a wavelength of 405 nm by the Varioskan Lux Reader (Thermo Fisher Scientific). After each incubation step, plates were washed three times with 100µl/well of washing buffer (phosphate-buffered saline, 0.05% Tween-20). Sample buffer was used as a blank and the threshold for sample positivity was set at 2-fold the optical density (OD) of the blank.

ELISA assay with RBD, NTD and S2 subunits

mAbs identification and plasma screening of vaccinees against RBD, NTD or S2 SARS-CoV-2 protein were performed by ELISA. Briefly, 3 µg/mL of RBD, NTD or S2 SARS-CoV-2 protein diluted in carbonate-bicarbonate buffer (E107, Bethyl laboratories) were coated in 384-well plates (microplate clear, Greiner Bio-one). After overnight incubation at 4°C, plates were washed 3 times with washing buffer (phosphate-buffered saline, 0.05% Tween-20) and blocked with 50 µL/well of blocking buffer (phosphate-buffered saline, 1% BSA) for 1h at 37°C. After washing, plates were incubated 1 h at 37 °C with mAbs diluted 1:5 in samples buffer (phosphate-buffered saline, 1% BSA, 0.05% Tween-20) or with plasma at a starting dilution 1:10 and step diluted 1:2 in sample buffer. Wells with no sample added were consider blank controls. Anti-Human IgG –Peroxidase antibody (Fab specific) produced in goat (Sigma) diluted 1:45000 in sample buffer was then added and samples were incubated for 1 h at 37°C. Plates were then washed, incubated with TMB substrate (Sigma) for 15 min before adding the stop solution (H₂SO₄ 0.2M). The OD values were identified using the Varioskan Lux Reader (Thermo Fisher Scientific) at 450 nm. Each condition was tested in triplicate and samples tested were considered positive if OD value was 2-fold the blank.

Flow cytometry-based competition assay

To classify mAbs candidates on the basis of their interaction with Spike epitopes, we performed a flow cytometry-based competition assay. In detail, magnetic beads (Dynabeads His-Tag, Invitrogen) were coated with histidine tagged S protein according to the manufacturers' instructions. Then, 20 µg/ml of coated S-protein-beads were pre-incubated with unlabeled nAbs candidates diluted 1:2 in PBS for 40 minutes at RT. After incubation, the mix Beads-antibodies was washed with 100 µL of PBS-BSA 1%. Then, to analyze epitope competition, mAbs able to bind RBD (J08, S309), NTD (4A8) or S2 (L19) domain of the S-protein were labeled with 4 different fluorophores (Alexa Fluor 647, 488, 594 and 405) using Alexa Fluor NHS Ester kit (Thermo Scientific), were mixed and incubated with S-protein-beads. Following 40 minutes of incubation at RT, the mix Beads-antibodies was washed with PBS, resuspended in 150 µL of PBS-BSA 1% and analyzed using BD LSR II flow cytometer (Becton Dickinson). Beads with or without S-protein incubated with labeled antibodies mix were used as positive and negative control respectively. Analysis was performed using FlowJo (version 10).

SARS-CoV-2 authentic viruses neutralization assay

All SARS-CoV-2 authentic virus neutralization assays were performed in the biosafety level 3 (BSL3) laboratories at Toscana Life Sciences in Siena (Italy) and Vismederi Srl, Siena (Italy). BSL3 laboratories are approved by a Certified Biosafety Professional and are inspected every year by local authorities. To evaluate the neutralization activity of identified nAbs against SARS-CoV-2 and all VoCs and evaluate the breadth of neutralization of this antibody is a cytopathic effect-based microneutralization assay (CPE-MN) was performed³. Briefly, the CPE-based neutralization assay sees the co-incubation of J08 with a SARS-CoV-2 viral solution containing 100 TCID₅₀ of virus and after 1 hour incubation at 37°C, 5% CO₂. The mixture was then added to the wells of a 96-well plate containing a sub-confluent Vero E6 cell monolayer. Plates were incubated for 3-4 days at 37°C in a humidified environment with 5% CO₂, then examined for CPE by means of an inverted optical microscope by two independent operators. All nAbs were tested a starting dilution of 1:5 and the IC₁₀₀ evaluated based on their initial concentration while plasma samples were tested starting from a 1:10 dilution. Both nAbs and plasma samples were then diluted step 1:2. Technical duplicates were performed for both nAbs and plasma samples. In each plate positive and negative control were used as previously described³.

SARS-CoV-2 virus variants CPE-MN neutralization assay

The SARS-CoV-2 viruses used to perform the CPE-MN neutralization assay were the original Wuhan SARS-CoV-2 virus (SARS-CoV-2/INMI1-Isolate/2020/Italy: MT066156), SARS-CoV-2 B.1.1.7 (INMI GISAID accession number: EPI_ISL_736997), SARS-CoV-2 B.1.351 (EVAg Cod: 014V-04058), B.1.1.248 (EVAg CoD: 014V-04089) and B.1.617.2 (GISAID ID: EPI_ISL_2029113)²⁶.

Single cell RT-PCR and Ig gene amplification and transcriptionally active PCR expression

The whole process for nAbs heavy and light chain recovery, amplification and transcriptionally active PCR (TAP) expression was performed as previously described³. Briefly, 5 µL of cell lysate were mixed with 1 µL of random hexamer primers (50 ng/µL), 1 µL of dNTP-Mix (10 mM), 2 µL 0.1 M DTT, 40 U/µL RNase OUT, MgCl₂ (25 mM), 5x FS buffer and Superscript IV reverse transcriptase (Invitrogen) to perform RT-PCR. Reverse transcription (RT) reaction was performed at 42°C/10', 25°C/10', 50°C/60' and 94°/5'. Two rounds of PCR were performed to obtain the heavy (VH) and light (VL) chain amplicons. All PCR reactions were performed in a nuclease-free water (DEPC) in a total volume of 25 µL/well. For PCR I, 4 µL of cDNA were mixed with 10 µM of VH and 10 µM VL primer-mix, 10mM dNTP mix, 0.125 µL of Kapa Long Range Polymerase (Sigma), 1.5 µL MgCl₂ and 5 µL of 5x Kapa Long Range Buffer. PCR I reaction was performed at 95°/3', 5 cycles at 95°C/30", 57°C/30", 72°C/30" and 30 cycles at 95°C/30", 60°C/30", 72°C/30" and a final extension of 72°/2'. Nested PCR II was performed as above starting from 3.5 µL of unpurified PCR I product. PCR II products were purified by Millipore MultiScreen® PCRµ96 plate according to manufacture instructions and eluted in 30 µL of nuclease-free water (DEPC). As for TAP expression, vectors were initially digested using restriction enzymes AgeI, Sall and Xho as previously described and PCR II

products ligated by using the Gibson Assembly NEB into 25 ng of respective human Igγ1, Igκ and Igλ expression vectors^{27,28}. TAP reaction was performed using 5 μL of Q5 polymerase (NEB), 5 μL of GC Enhancer (NEB), 5 μL of 5X buffer, 10 mM dNTPs, 0.125 μL of forward/reverse primers and 3 μL of ligation product, using the following cycles: 98°/2', 35 cycles 98°/10", 61°/20", 72°/1' and 72°/5'.

Functional repertoire analyses

nAbs VH and VL sequence reads were manually curated and retrieved using CLC sequence viewer (Qiagen). Aberrant sequences were removed from the data set. Analyzed reads were saved in FASTA format and the repertoire analyses was performed using Cloanalyst (<http://www.bu.edu/computationalimmunology/research/software/>)^{29,30}.

Statistical analysis

Statistical analysis was assessed with GraphPad Prism Version 8.0.2 (GraphPad Software, Inc., San Diego, CA). Nonparametric Mann-Whitney t test was used to evaluate statistical significance between the two groups analyzed in this study. Statistical significance was shown as * for values ≤ 0.05, ** for values ≤ 0.01, *** for values ≤ 0.001, and **** for values ≤ 0.0001.

Data availability

All data supporting the findings in this study are available within the article or can be obtained from the corresponding author upon request.

ACKNOWLEDGMENTS

This work was funded by the European Research Council (ERC) advanced grant agreement number 787552 (vAMRes). This publication was supported by funds from the “Centro Regionale Medicina di Precisione” and by all the people who answered the call to fight with us the battle against SARS-CoV-2 with their kind donations on the platform ForFunding (<https://www.forfunding.intesasanpaolo.com/DonationPlatform-ISP/nav/progetto/id/3380>). This work was funded by COOP ITALIA Soc. Coop. This publication was supported by the European Virus Archive goes Global (EVAg) project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 653316. This publication was supported by the COVID-2020-12371817 project, which has received funding from the Italian Ministry of Health. We would also like to acknowledge Dr. Jason McLellan, for kindly providing the S protein trimer, RBD, NTD and S2 constructs, and Dr. Olivier Schwartz, for providing the B.1.617.2 (delta) SARS-CoV-2 variant. We would like to thank the nurse staff of the operative unit of the department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy, and all the COVID-19 vaccinated donors for participating to this study.

AUTHOR CONTRIBUTIONS

EA and RR conceived the project. FM, MF, IR and MT enrolled COVID-19 vaccinees to the study. EA and IP performed PBMC isolation and single cell sorting. IP performed ELISAs and competition assays. IP and NM recovered nAbs VH and VL and expressed antibodies. PP and EA recovered VH and VL sequences and performed the repertoire analyses. EP and VA produced and purified SARS-CoV-2 S protein constructs. EA, GP, IH, ML, LB and GG performed neutralization assays in BSL3 facilities. CDS supported day-by-day laboratory activities and management. EA and RR wrote the manuscript. All authors contributed to the final revision of the manuscript. EA, CS, EM and RR coordinated the project.

DECLARATION OF INTERESTS

Rino Rappuoli is an employee of GSK group of companies. EA, IP, NM, PP, EP, CDS, CS and RR are listed as inventors of full-length human monoclonal antibodies described in Italian patent applications n. 102020000015754 filed on June 30th 2020, 102020000018955 filed on August 3rd 2020 and 102020000029969 filed on 4th of December 2020, and the international patent system number PCT/IB2021/055755 filed on the 28th of June 2021.

396 **FIGURES**

Figure 1. Identification of cross-neutralizing SARS-CoV-2 S protein-specific nAbs. (A) The graph shows supernatants tested for binding to the Wuhan SARS-CoV-2 S protein antigen stabilized in its prefusion conformation. Threshold of positivity has been set as two times the value of the blank (dotted line). Dark blue and red dots represent mAbs that bind to the S protein for seronegative and seropositive vaccinees respectively. Light blue and red dots represent mAbs that do not bind the S protein for seronegative and seropositive vaccinees. (B) The bar graph shows the percentage of not-neutralizing (gray), neutralizing mAbs from seronegatives (dark blue), and neutralizing mAbs for seropositives (dark red). The total number (n) of antibodies tested per individual is shown on top of each bar (C) Graphs show the fold change percentage of nAbs in seronegatives and seropositives against the alpha, beta and gamma VoCs compared to the original Wuhan SARS-CoV-2 virus. The heatmaps show the overall percentage of Wuhan SARS-CoV-2 nAbs able to neutralize tested VoCs.

409

410 **Figure 2. Potency and breadth of neutralization of nAbs against SARS-CoV-2 and VoCs. (A - E)**

411 Scatter dot charts show the neutralization potency, reported as IC₁₀₀ (ng/mL), of nAbs tested against

412 the original Wuhan SARS-CoV-2 virus (A) and the B.1.1.7 (B), B.1.351 (C), B.1.1.248 (D) and

413 B.1.617.2 (E) VoCs. The number and percentage of nAbs from seronegatives vs seropositives, fold-

414 change and statistical significance are denoted on each graph. A nonparametric Mann-Whitney t test

415 was used to evaluate statistical significances between groups. Significances are shown as *p < 0.05,

416 **p < 0.01, ***p < 0.001, and ****p < 0.0001. (F) The table shows the IC₁₀₀ geometric mean (GM) of
417 all nAbs pulled together from each group against all SARS-CoV-2 viruses tested.

Figure 3. Repertoire analyses and functional characterization of predominant gene derived nAbs.

(A) The graph shows the IGHV-J rearrangement frequencies between seronegative and seropositive vaccinees (top panel), the frequency within subjects (middle panels) and the Log2 fold change (FC) between groups (bottom panel). (B - G) Graphs show the neutralization potency (IC_{100}) of predominant gene derived nAbs from the IGHV1-2;IGHJ6-1 (B), IGHV1-69;IGHJ4-1 (C), IGHV2-5;IGHJ4-1 (D), IGHV3-30;IGHJ6-1 (E), IGHV3-53;IGHJ6-1 (F) and IGHV3-66;IGHJ4-1 (G) families, against the original Wuhan SARS-CoV-2 virus and the B.1.1.7, B.1.351, B.1.1.248 and B.1.617.2 VoCs.

SUPPLEMENTARY TABLES

Subject ID	Gender	Age	Previous COVID-19 negative test	COVID-19 positive test	Type of test	Severity of Infection	SARS-CoV-2 Serology	First Dose	Second Dose	Blood Collection
VAC-001	M	38	16/12/2020	Not-applicable	Swab	Not-applicable	Seronegative	27/12/2020	18/01/2021	02/03/2021
VAC-002	F	38	31/12/2020	Not-applicable	Swab	Not-applicable	Seronegative	01/01/2021	22/01/2021	02/03/2021
VAC-007	M	38	29/12/2020	Not-applicable	Swab	Not-applicable	Seronegative	04/01/2021	25/01/2021	31/03/2021
VAC-008	M	43	28/12/2020	Not-applicable	Swab	Not-applicable	Seronegative	03/01/2021	24/01/2021	31/03/2021
VAC-010	F	51	15/02/2021	Not-applicable	Swab	Not-applicable	Seronegative	18/02/2021	11/03/2021	07/04/2021
VAC-003	M	38	15/10/2020	26/10/2020	Swab	Asymptomatic	Seropositive	08/01/2021	15/02/2021	09/03/2021
VAC-004	F	25	Not-applicable	22/10/2020	Swab	Mild	Seropositive	08/02/2021	01/03/2021	09/03/2021
VAC-005	M	25	01/08/2020	02/11/2020	Serological	Mild	Seropositive	11/01/2021	16/02/2021	16/03/2021
VAC-006	F	57	27/04/2020	24/10/2020	Swab	Asymptomatic	Seropositive	16/01/2021	11/02/2021	16/03/2021
VAC-009	M	46	29/09/2020	06/11/2020	Serological	Moderate	Seropositive	20/03/2021	Not-applicable	07/04/2021

Table S1. Clinical details of COVID-19 vaccinees. This table summarizes all the clinically relevant information for the 5 seropositive and 5 seronegative vaccinated donors enrolled in this study.

Subject	SARS-CoV-2 serology	S-protein+ MBCs Sorted	S-protein+ mAbs (n)	S-protein+ mAbs (%)	Wuhan - Neutralizing antibodies (n)	Wuhan - Neutralizing antibodies (%)	B.1.1.7 - Neutralizing antibodies (n)	B.1.1.7 - Neutralizing antibodies (%)	B.1.351 - Neutralizing antibodies (n)	B.1.351 - Neutralizing antibodies (%)	B.1.1.248 - Neutralizing antibodies (n)	B.1.1.248 - Neutralizing antibodies (%)
VAC-001	Seronegative	484	205	42.3	13	6.3	8	61.5	2	15.4	6	46.2
VAC-002	Seronegative	497	316	63.6	27	8.5	19	70.4	6	22.2	11	40.7
VAC-007	Seronegative	161	100	62.1	16	16.0	14	87.5	3	18.8	6	37.5
VAC-008	Seronegative	682	107	15.7	10	9.3	6	60.0	5	50.0	6	60.0
VAC-010	Seronegative	528	216	40.9	5	2.3	3	60.0	0	0.0	2	40.0
Total (Seronegative)		2,352	944	40.1	71	7.5	50	70.4	16	22.5	31	43.6
VAC-003	Seropositive	616	428	69.5	78	18.2	58	74.4	25	32.1	40	51.3
VAC-004	Seropositive	506	318	62.8	31	9.7	24	77.4	11	35.5	18	58.1
VAC-005	Seropositive	924	601	65.0	152	25.3	132	86.8	78	51.3	114	75.0
VAC-006	Seropositive	396	216	55.8	19	8.8	12	63.2	5	26.3	8	42.1
VAC-009	Seropositive	1,090	736	67.5	60	8.1	48	80.0	15	25.0	31	51.7
Total (Seropositive)		3,532	2,299	65.1	340	14.8	274	80.6	134	39.4	211	62.0

Table S2. Summary of COVID-19 vaccinees. This table summarizes the number and percentages of single cell sorted S protein-specific MBCs, number and percentages of S protein binding mAbs, and neutralizing mAbs against the original Wuhan SARS-CoV-2 virus and VoCs. This table includes only data from the initial screening where nAbs were tested at a single point dilution against the original Wuhan virus and the B.1.1.7, B.1.351 and B.1.1.248 VoCs. At this stage the B.1.617.2 (delta) variant was not available.

Subject	SARS-CoV-2 serology	Distribution Competition J08 (n)	Distribution Competition J08 (%)	Distribution Competition S309 (n)	Distribution Competition S309 (%)	Distribution Competition 4A8 (n)	Distribution Competition 4A8 (%)	Distribution Competition L19 (n)	Distribution Competition L19 (%)	Distribution Competition Not-competing (n)	Distribution Competition Not-competing (%)
VAC-001	Seronegative	4	50.0	0	0.0	1	12.5	0	0.0	3	37.5
VAC-002	Seronegative	7	41.2	1	5.9	2	11.8	0	0.0	7	41.2
VAC-007	Seronegative	9	60.0	3	20.0	2	13.3	0	0.0	1	6.7
VAC-008	Seronegative	4	44.4	0	0.0	3	33.3	0	0.0	2	22.2
VAC-010	Seronegative	2	66.7	0	0.0	1	33.3	0	0.0	0	0.0
Total (Seronegative)		26	50.0	4	7.7	9	17.3	0	0.0	13	25.0
VAC-003	Seropositive	19	54.3	7	20.0	3	8.6	0	0.0	6	17.1
VAC-004	Seropositive	2	15.4	7	53.8	0	0.0	0	0.0	4	30.8
VAC-005	Seropositive	58	51.3	25	22.1	19	16.8	0	0.0	11	9.7
VAC-006	Seropositive	8	61.5	2	15.4	1	7.7	0	0.0	2	15.4
VAC-009	Seropositive	28	56.0	7	14.0	12	24.0	0	0.0	3	6.0
Total (Seropositive)		115	51.3	48	21.4	35	15.6	0	0.0	26	11.6

Table S3. Competition assay. This table summarizes the number and percentages of competing nAbs from seronegative and seropositive vaccinees against J08, S309, 4A8 and L19. Not-competing nAbs are also reported in this table.

450 SUPPLEMENTARY FIGURES

Figure S1. Single cell sorting and memory B cell frequencies. (A) The gating strategy shows from left to right: CD19⁺ B cells; CD19⁺CD27⁺IgD⁻; CD19⁺CD27⁺IgD-IgM⁻/IgM⁺; CD19⁺CD27⁺IgD-IgM-Sprotein⁺; CD19⁺CD27⁺IgD-IgM⁺Sprotein⁺. (B) The graph shows the frequency of CD19⁺CD27⁺IgD-IgM⁻ and IgM⁺. (C) The graph shows the frequency of CD19⁺CD27⁺IgD-IgM⁻ and IgM⁺ able to bind the SARS-CoV-2 S protein trimer (S protein⁺). (D) The table summarizes the frequencies of the cell population above described for all subjects enrolled in our study.

Figure S2. Plasma response of COVID-19 vaccinees. (A - D) Graphs show the ability of plasma samples from seronegative and seropositive vaccinees to bind the S protein trimer (A), RBD (B), NTD (C) and S2 domain (D). (E) The graph shows the neutralizing activity of plasma samples against the original Wuhan SARS-CoV-2 virus. (F) The table summarizes the 100% inhibitory dilution (ID₁₀₀) of each COVID-19 vaccinee and the geometric mean for seronegative and seropositive donors.

464

465

466

467

Figure S3. RBD and NTD binding distribution of nAbs. The graph shows the percentage of antibodies that bind specifically the RBD (light orange) or the NTD (cyan) or that did not bind single domains but recognized exclusively the S protein in its trimetric conformation (gray).

468

469 **Figure S4. Heavy chain CDR3 length and somatic hypermutation levels in seronegative and**
 470 **seropositive vaccinees.** (A) The graph shows the heavy chain CDR3 length represented in amino
 471 acids (aa). (B) The graph shows the overall somatic hypermutation level of nAbs isolated from
 472 seronegative and seropositive vaccinees.

473

474

475

476

477

478

Figure S5. Heavy chain CDR3 length and somatic hypermutation levels of predominant gene derived nAbs. (A - F) Graphs show the amino acidic heavy chain CDR3 length (left panel) and the somatic hypermutation level (right panel) of nAbs derived from the IGHV1-2;IGHJ6-1 (A), IGHV1-69;IGHJ4-1 (B), IGHV2-5;IGHJ4-1 (C), IGHV3-30;IGHJ6-1 (D), IGHV3-53;IGHJ6-1 (E) and IGHV3-66;IGHJ4-1 (F) gene families.

479

480

481

482

483

484

485

Figure S6. Heavy chain CDR3 length and somatic hypermutation levels of predominant gene derived nAbs. (A) Schematic representation of the epitopes recognized by J08 (dark red), S309 (orange), 4A8 (dark blue) and L19 (gold), mAbs on the S protein surface. (B - E) Representative cytometer peaks per each of the four mAbs used for the competition assay. Positive (beads conjugated with only primary labeled antibody) and negative (un-conjugated beads) controls are shown as green and gray peaks, respectively.

REFERENCES

- 1 Wajnberg, A. *et al.* Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. **370**, 1227-1230, doi:10.1126/science.abd7728 %J Science (2020).
- 2 Xiaojie, S., Yu, L., lei, Y., Guang, Y. & Min, Q. Neutralizing antibodies targeting SARS-CoV-2 spike protein. *Stem Cell Research* **50**, 102125, doi:<https://doi.org/10.1016/j.scr.2020.102125> (2021).
- 3 Andreano, E. *et al.* Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. *Cell* **184**, 1821-1835.e1816, doi:<https://doi.org/10.1016/j.cell.2021.02.035> (2021).
- 4 Yang, Y. & Du, L. SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies. *Signal Transduction and Targeted Therapy* **6**, 95, doi:10.1038/s41392-021-00523-5 (2021).
- 5 Clausen, T. M. *et al.* SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. *Cell* **183**, 1043-1057.e1015, doi:<https://doi.org/10.1016/j.cell.2020.09.033> (2020).
- 6 Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. **367**, 1260-1263, doi:10.1126/science.abb2507 %J Science (2020).
- 7 Piccoli, L. *et al.* Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* **183**, 1024-1042.e1021, doi:10.1016/j.cell.2020.09.037 (2020).
- 8 Tortorici, M. A. *et al.* Broad sarbecovirus neutralization by a human monoclonal antibody. *Nature*, doi:10.1038/s41586-021-03817-4 (2021).
- 9 Andreano, E. & Rappuoli, R. Immunodominant antibody germ lines in COVID-19 Immunodominant antibody germ lines in COVID-19. *Journal of Experimental Medicine* **218**, doi:10.1084/jem.20210281 (2021).
- 10 Yuan, M. *et al.* Structural basis of a shared antibody response to SARS-CoV-2. **369**, 1119-1123, doi:10.1126/science.abd2321 %J Science (2020).
- 11 Callaway, E. Coronavirus variants get Greek names - but will scientists use them? *Nature* **594**, 162, doi:10.1038/d41586-021-01483-0 (2021).
- 12 Stamatatos, L. *et al.* mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. **372**, 1413-1418, doi:10.1126/science.abg9175 %J Science (2021).
- 13 Goel, R. R. *et al.* Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination. **6**, eabi6950, doi:10.1126/sciimmunol.abi6950 %J Science Immunology (2021).
- 14 Urbanowicz, R. A. *et al.* Two doses of the SARS-CoV-2 BNT162b2 vaccine enhances antibody responses to variants in individuals with prior SARS-CoV-2 infection. eabj0847, doi:10.1126/scitranslmed.abj0847 %J Science Translational Medicine (2021).

523 15 Crotty, S. Hybrid immunity. **372**, 1392-1393, doi:10.1126/science.abj2258 %J Science
524 (2021).

525 16 Wang, Z. *et al.* Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after
526 infection. *Nature* **595**, 426-431, doi:10.1038/s41586-021-03696-9 (2021).

527 17 Zhang, Q. *et al.* Potent and protective IGHV3-53/3-66 public antibodies and their shared
528 escape mutant on the spike of SARS-CoV-2. *Nature Communications* **12**, 4210,
529 doi:10.1038/s41467-021-24514-w (2021).

530 18 Pinto, D. *et al.* Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV
531 antibody. *Nature* **583**, 290-295, doi:10.1038/s41586-020-2349-y (2020).

532 19 Chi, X. *et al.* A neutralizing human antibody binds to the N-terminal domain of the Spike
533 protein of SARS-CoV-2. **369**, 650-655, doi:10.1126/science.abc6952 %J Science (2020).

534 20 Voss, W. N. *et al.* Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-
535 RBD spike epitopes. **372**, 1108-1112, doi:10.1126/science.abg5268 %J Science (2021).

536 21 Li, B. *et al.* Viral infection and transmission in a large, well-traced outbreak caused by the
537 SARS-CoV-2 Delta variant. 2021.2007.2007.21260122, doi:10.1101/2021.07.07.21260122
538 %J medRxiv (2021).

539 22 Meng, B. *et al.* Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
540 the Alpha variant B.1.1.7. *Cell Reports* **35**, doi:10.1016/j.celrep.2021.109292 (2021).

541 23 Steichen, J. M. *et al.* A generalized HIV vaccine design strategy for priming of broadly
542 neutralizing antibody responses. **366**, eaax4380, doi:10.1126/science.aax4380 %J Science
543 (2019).

544 24 Havenar-Daughton, C., Abbott, R. K., Schief, W. R. & Crotty, S. When designing vaccines,
545 consider the starting material: the human B cell repertoire. *Current opinion in immunology*
546 **53**, 209-216, doi:10.1016/j.coi.2018.08.002 (2018).

547 25 Huang, J. *et al.* Isolation of human monoclonal antibodies from peripheral blood B cells.
548 *Nature Protocols* **8**, 1907-1915, doi:10.1038/nprot.2013.117 (2013).

549 26 Planas, D. *et al.* Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to
550 neutralizing antibodies. *Nature Medicine* **27**, 917-924, doi:10.1038/s41591-021-01318-5
551 (2021).

552 27 Tiller, T. *et al.* Efficient generation of monoclonal antibodies from single human B cells by
553 single cell RT-PCR and expression vector cloning. *J Immunol Methods* **329**, 112-124,
554 doi:10.1016/j.jim.2007.09.017 (2008).

555 28 Wardemann, H. & Busse, C. E. Expression Cloning of Antibodies from Single Human B Cells.
556 *Methods in molecular biology (Clifton, N.J.)* **1956**, 105-125, doi:10.1007/978-1-4939-9151-
557 8_5 (2019).

558 29 Kepler, T. B. Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved
559 ancestors. *F1000Res* **2**, 103-103, doi:10.12688/f1000research.2-103.v1 (2013).

560 30 Kepler, T. B. *et al.* Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity
561 Maturation. **5**, doi:10.3389/fimmu.2014.00170 (2014).